Search
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Categories: Heterocyclic Compounds with 4 or More RingsPlosaracetam
go.drugbank.com/drugs/DB21594InvestigationalPlosaracetam is under investigation in clinical trial NCT05199142 (A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive
Tromantadine
go.drugbank.com/drugs/DB13288ApprovedTromantadine is marketed as Viru-Merz in the Czech Republic . It is an antiviral used in the treatment of herpes zoster and simplex.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTalbutal
go.drugbank.com/drugs/DB00306ApprovedIllicitTalbutal, also called 5-allyl-5-sec-butylbarbituric acid, is a barbiturate with a short to intermediate duration of action. Talbutal is a schedule III drug in the U.S.
MK-1496
go.drugbank.com/drugs/DB12763InvestigationalMK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.
MK-5108
go.drugbank.com/drugs/DB12556InvestigationalMK-5108 has been used in trials studying the treatment of Cancer, Neoplasms, Tumors.
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.
Tiagabine
go.drugbank.com/drugs/DB00906ApprovedIt is also used in the treatment for panic disorder as are a few other anticonvulsants.
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalIt is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb.
Pomaglumetad methionil
go.drugbank.com/drugs/DB05096InvestigationalLY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.